Nurix Therapeutics, Inc. NRIX Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $247.93M+124% | $110.9M+99.7% | $55.53M-15.1% | $65.38M-18.8% | ||
| $606.82M-2.0% | $619.39M+110% | $295.5M-7.2% | $318.45M+2.4% | ||
| $22.49M+26.7% | $17.76M+5.6% | $16.81M-2.1% | $17.16M+51.3% | ||
| $688.14M+2.8% | $669.34M+88.2% | $355.6M-14.7% | $416.76M-12.6% | ||
| $11.22M-2.3% | $11.48M+79.4% | $6.4M+26.4% | $5.06M-23.8% | ||
| $17.58M-54.2% | $38.36M-20.2% | $48.1M+27.8% | $37.63M-8.7% | ||
| $86.47M-9.8% | $95.85M+10.2% | $86.96M+23.1% | $70.66M+6.6% | ||
| $149.39M+4.9% | $142.35M-8.2% | $155.11M+37.2% | $113.06M-15.9% | ||
| 500M0.0% | 500M+1,020,308% | 49K+4.3% | 47K+4.4% | ||
| -$1B-35.8% | -$738.77M-35.5% | -$545.2M-35.9% | -$401.25M-81.7% | ||
| $538.75M+2.2% | $526.99M+163% | $200.49M-34.0% | $303.7M-11.3% | ||
| $688.14M+2.8% | $669.34M+88.2% | $355.6M-14.7% | $416.76M-12.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Nurix Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 6.01 — current assets exceed current liabilities.
- Where does Nurix Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Nurix Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.